Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Grifols says its investment enhances its range of products

Grifols says its investment enhances its range of products

5th March 2009

Grifols has gained control of a firm it says will enhance and complement its range of products for blood typing and pretransfusion diagnostics.

Through a 25 million euro (22.24 million pounds) investment, Grifols has acquired 49 per cent of the stocks – and gained control – of a Swiss and Australian group.

Medion Diagnostics AG, which is located in Switzerland, has developed a new technology in a blood group serology which has the high level of automation, safety and productivity that the sector requires.

Under the agreement, the two companies will invest in the final development of this advancement and it is believed that every market Grifols operates in will benefit from the availability of the new products manufactured in Switzerland.

As part of the same deal, Grifols will also obtain the license for Flebogamma and will begin selling this biological treatment during the first quarter of the year.

It will also be able to reaffirm and expand its presence in the diagnostics market in Australia and New Zealand.

Grifols researches, develops, manufactures and markets diagnostic systems, medical materials, plasma derivatives, IV therapies and enteral nutritions.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.